Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/163357
Title: | Designing siRNA/chitosan-methacrylate complex nanolipogel for prolonged gene silencing effects | Authors: | Cao, Ye Tan, Yang Fei Wong, Yee Shan Aminuddin, Muhammad Ramya, Bhuthalingam Liew, Melvin Wen Jie Liu, Jiaxin Venkatraman, Subbu S. |
Keywords: | Engineering::Materials | Issue Date: | 2022 | Source: | Cao, Y., Tan, Y. F., Wong, Y. S., Aminuddin, M., Ramya, B., Liew, M. W. J., Liu, J. & Venkatraman, S. S. (2022). Designing siRNA/chitosan-methacrylate complex nanolipogel for prolonged gene silencing effects. Scientific Reports, 12(1), 3527-. https://dx.doi.org/10.1038/s41598-022-07554-0 | Journal: | Scientific Reports | Abstract: | Despite immense revolutionary therapeutics potential, sustaining release of active small interfering RNA (siRNA) remains an arduous challenge. The development of nanoparticles with siRNA sustained release capabilities provides an avenue to enhance the therapeutic efficacy of gene-based therapy. Herein, we present a new system based on the encapsulation of siRNA/chitosan-methacrylate (CMA) complexes into liposomes to form UV crosslinkable Nanolipogels (NLGs) with sustained siRNA-release properties in vitro. We demonstrated that the CMA nanogel in NLGs can enhance the encapsulation efficiency of siRNA and provide sustained release of siRNA up to 28 days. To understand the particle mechanism of cellular entry, multiple endocytic inhibitors have been used to investigate its endocytosis pathways. The study saw positively charged NLGs entering cells via multiple endocytosis pathways, facilitating endosomal escape and slowly releasing siRNA into the cytoplasm. Transfection experiments confirmed that the crosslinked NLG delivery system provides effective transfection and prolonged silencing effect up to 14 days in cell cultures. We expect that this sustained-release siRNA NLG platform would be of interest in both fundamental biological studies and in clinical applications to extend the use of siRNA-based therapies. | URI: | https://hdl.handle.net/10356/163357 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-022-07554-0 | Rights: | © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | MSE Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ContentServer (7).pdf | 2.78 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
50
2
Updated on Jan 26, 2023
Web of ScienceTM
Citations
50
2
Updated on Jan 28, 2023
Page view(s)
13
Updated on Jan 30, 2023
Download(s)
8
Updated on Jan 30, 2023
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.